David Lebowitz

Stock Analyst at Citigroup

(0)
# 3885
Out of 5,243 analysts
102
Total ratings
45.16%
Success rate
-2.43%
Average return
23 Stocks
Name Action Price Target Current % Upside Ratings Updated
PTC Therapeutics
Maintains: Sell
26 32
42.18 -24.13% 3 Dec 4, 2024
Mirum Pharmaceutical...
Maintains: Strong Buy
65 68
46.49 46.27% 4 Nov 13, 2024
Incyte
Maintains: Strong Buy
92 97
72.42 33.94% 4 Oct 30, 2024
Intellia Therapeutic...
Maintains: Neutral
25 19
9.83 93.29% 6 Oct 25, 2024
Celldex Therapeutics
Initiates Coverage On: Buy
70
22.96 204.88% 1 Oct 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
13 15
8.13 84.5% 3 Sep 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
178 207
133.1 55.52% 12 Sep 17, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
45 44
11.63 278.33% 4 May 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Sell
65 76
106.98 -28.96% 5 May 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
39 37
19.52 89.55% 9 May 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
382
272.1 40.39% 1 Mar 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
42 46
35.46 29.72% 2 Feb 23, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
31
36.83 -15.83% 1 Dec 15, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
36 60
33.2 80.72% 11 Jul 31, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
103 96
62.85 52.74% 3 Jun 30, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
18 12
2.01 497.01% 2 Jul 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
170 164
252.24 -34.98% 7 Jul 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
36 39
13.7 184.67% 6 Jun 7, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
20 21
12.87 63.17% 11 Oct 12, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
29 27
0.63 4185.71% 1 Oct 12, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
13 14
3.79 269.39% 2 Oct 12, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
324 300
n/a n/a 2 Oct 12, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Underweight
10 5
n/a n/a 2 Aug 10, 2021